Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Index- P/E32.51 EPS (ttm)1.61 Insider Own- Shs Outstand2.67B Perf Week1.06%
Market Cap139.90B Forward P/E13.17 EPS next Y3.98 Insider Trans- Shs Float2.38B Perf Month3.73%
Income4.26B PEG4.06 EPS next Q- Inst Own8.60% Short Float0.19% Perf Quarter2.27%
Sales46.40B P/S3.02 EPS this Y-12.80% Inst Trans-0.07% Short Ratio2.52 Perf Half Y6.19%
Book/sh29.22 P/B1.79 EPS next Y12.77% ROA3.10% Target Price56.21 Perf Year3.05%
Cash/sh2.16 P/C24.26 EPS next 5Y8.00% ROE5.40% 52W Range46.95 - 55.94 Perf YTD-2.41%
Dividend1.91 P/FCF- EPS past 5Y-0.80% ROI7.20% 52W High-6.44% Beta1.11
Dividend %3.65% Quick Ratio1.00 Sales past 5Y4.20% Gross Margin67.20% 52W Low11.48% ATR0.77
Employees112128 Current Ratio1.50 Sales Q/Q-7.80% Oper. Margin17.70% RSI (14)56.79 Volatility1.23% 1.24%
OptionableYes Debt/Eq0.26 EPS Q/Q-22.20% Profit Margin9.10% Rel Volume0.49 Prev Close51.67
ShortableYes LT Debt/Eq0.19 EarningsFeb 09 BMO Payout120.20% Avg Volume1.74M Price52.34
Recom1.70 SMA201.18% SMA502.67% SMA2002.45% Volume856,071 Change1.30%
03-Aug-12Downgrade Standpoint Research Buy → Hold
11-Jan-11Downgrade Jefferies Buy → Hold
16-Nov-09Initiated Deutsche Securities Buy
14-Oct-09Upgrade UBS Sell → Neutral
28-Aug-09Upgrade JP Morgan Neutral → Overweight
29-Jun-09Downgrade JP Morgan Overweight → Neutral
28-May-09Upgrade Citigroup Hold → Buy
30-Apr-09Upgrade JP Morgan Neutral → Overweight
23-Mar-09Upgrade Jefferies & Co Underperform → Hold
17-Mar-09Initiated Credit Suisse Outperform
19-Feb-09Upgrade JP Morgan Underweight → Neutral
26-Jan-09Initiated Jefferies & Co Underperform
07-Nov-08Downgrade UBS Neutral → Sell
23-Sep-08Downgrade Credit Suisse Neutral → Underperform
24-Oct-07Initiated Bernstein Mkt Perform
06-Sep-07Initiated UBS Neutral
18-Jul-07Upgrade HSBC Securities Neutral → Overweight
14-Jun-07Reiterated Banc of America Sec Buy $50 → $48
14-Jun-07Downgrade JP Morgan Overweight → Neutral
14-Jun-07Downgrade HSBC Securities Overweight → Neutral
17-Apr-14 05:16PM  Impax to Sell Authorized Generic Renvela Zacks
09:32AM  Earnings Primer: What's on Deck for Amgen Inc. and Biogen Idec Inc. at Motley Fool
16-Apr-14 03:23PM  Why this biotech is rushing in as big pharma exits at CNBC
03:23PM  As big pharma backs away, Alnylam sees deja vu at CNBC
11:14AM  Down 17%: Is Isis Pharmaceuticals Worth Buying Now? at Motley Fool
10:40AM  Prestige Brands Gains on Product Acquisition News Zacks
09:23AM  New Stock Coverage: Use (Don't Lose) Your Head in Regeneron at Minyanville
08:07AM  Can Once Daily GLP-1 Lyxumia Be The Next Major Growth Driver For Sanofi? at Seeking Alpha
05:36AM  Neil Woodford's High Income Fund Farewell: Wm. Morrison Supermarkets plc, Rentokil Initial plc And Sanofi SA at Motley Fool
15-Apr-14 02:24PM  5-star stock picker Bill Nygren's new plays at CNBC
12:08PM  [video] Bill Nygren's new ideas at CNBC
09:05AM  Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend? at Motley Fool
09:04AM  Big Pharma's Turn On RNAi Shows That New Technologies Don't Guarantee R&D Success at Forbes
09:00AM  Basketball Hall of Famer Nancy Lieberman Teams Up with New NasacortĀ® Allergy 24HR to Help Allergy Sufferers Put the Full 'Cort Press on Nasal Allergy Symptoms PR Newswire
02:56AM  Sanofi Launches Probi DigestisĀ® in Korea Business Wire
14-Apr-14 10:00AM  The Cost to Treat Cholesterol Plummets, But Will It Last? at Motley Fool
13-Apr-14 10:00AM  Got Allergies? FDA to the Rescue at Motley Fool
12-Apr-14 03:06PM  2 Ways To Invest in This 1 Big Spending Trend at Motley Fool
11-Apr-14 03:30PM  Aegerion Shares Up on Study Initiation Zacks
11:55AM  Covis Pharma Holdings S.a r.l. -- Moody's revises Covis Pharma's outlook to positive at Moody's
08:32AM  Three Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha
08:32AM  3 Biotech Companies That Look To Be Good Buys After A Pullback at Seeking Alpha
10-Apr-14 11:43AM  [video] Pfizer CEO worries about ACA coverage at CNBC
11:06AM  Are Tapeworms The Conceptual Key To The Next Multiple Sclerosis Blockbuster? at Seeking Alpha
10:02AM  [video] Celgene CEO: Intellectual property is lifeblood of innovation at CNBC
08-Apr-14 09:38PM  Big Pharma Opens New Chapter On Big Data Collaboration at Forbes
06:10PM  Sanofi to File for Lemtrada Approval Again Zacks
12:10PM  In A Shaky Biotech Market, Alnylam's Prospects Are Getting Stronger at Seeking Alpha
10:20AM  The Biggest Biotech Clinical Wins of the Week at Motley Fool
08:01AM  Can Yahoo! Compete with Netflix and Amazon in the Original Video Market? at Motley Fool
08:01AM  3 Stocks Rising on Big Volume at TheStreet
07-Apr-14 05:20PM  ADT Corp. Initiates Debt Refinancing Zacks
12:46PM  FDA Grants Breakthrough Therapy Designation To Novartis' Meningitis B Vaccine at Forbes
12:46PM  FDA Breakthrough Therapy Designation For Novartis' Bexsero Vaccine To Prevent Meningitis B at Forbes
12:13PM  FDA Breakthrough Therapy Designation For Novartis' Bexsero Vaccine To Prevent Meningitis B at Forbes
08:34AM  Does Pfizer Belong in Your Portfolio? at Wall St. Cheat Sheet
01:00AM  Genzyme to Resubmit LemtradaTM Application for FDA Review Business Wire
05-Apr-14 07:49AM  Why Amazons Fire TV Should Scare Sony, Nintendo, and Microsoft at Motley Fool
04:12AM  [$$] 13D Filings at Barrons.com
04-Apr-14 06:00AM  At the Forefront of 4K: Intelsat, BT, Ericsson, Newtec and Sony Demonstrate Next Steps to Make True 4K UHDTV a Commercial Reality Business Wire
03-Apr-14 02:31PM  Does Amgen Have the Next Lipitor on Its Hands? at Motley Fool
02-Apr-14 04:25PM  3 Stocks to Get on Your Watchlist at Motley Fool
10:30AM  Encouraging Data on Sanofi/Regeneron's Alirocumab Zacks
06:00AM  Europe Moves to Make Drug Trial Data More Transparent at BusinessWeek
01-Apr-14 02:31PM  Can This Drive Growth for Amarin Corporation plc? at Motley Fool
09:13AM  Sanofi Pasteur Announces FDA Has Expanded Age Indication of AdacelĀ® Tdap Vaccine to Include Persons 10 Years of Age PR Newswire
08:39AM  Aastrom appoints Chief Scientific Officer, Chief Medical Officer theflyonthewall.com
08:16AM  Sanofi and Regeneron report positive results from Phase 2 study with alirocumab theflyonthewall.com
08:00AM  Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study PR Newswire
05:57AM  [$$] Three Reasons to Be Cautious on Pfizer at Barrons.com
31-Mar-14 05:50PM  Anacor Enrolls First Patient in Study Zacks
05:15PM  Why American Capital Ltd., Alnylam Pharmaceuticals Inc., and Micron Technology Inc. are Today's 3 Best Stocks at Motley Fool
01:59PM  Amgen Stock Gets Bump Up On Cholesterol Drug Data at Investor's Business Daily
01:36PM  Supreme Court to Hear Appeal of Generic Drug Case at New York Times
08:09AM  The Zacks Analyst Blog Highlights: Pfizer, Amgen, Sanofi, Alkermes and JPMorgan Chase Zacks
07:00AM  Amgen Drug Cuts Cholesterol Levels In Pivotal Studies at TheStreet
30-Mar-14 03:31PM  2 Obamacare Prescription Drug Assistance Programs Ending: What You Need to Know at Motley Fool
28-Mar-14 01:37PM  Encouraging Data on Pfizer Cholesterol Drug Zacks
12:11PM  This Rapidly Evolving New Cholesterol Treatment Pathway Demands Your Attention at Motley Fool
27-Mar-14 06:41PM  New Cholesterol Fighters To Take Center Stage At ACC at Investor's Business Daily
02:00AM  Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session PR Newswire
26-Mar-14 06:32PM  Where are They Now? Biotech IPO Class of 2013, March Edition at Motley Fool
04:58PM  Which Drugmaker Will Snap Up Mercks Consumer Health Unit? at Wall St. Cheat Sheet
04:17PM  Pfizer Gains Slightly on Xalkori Data Zacks
02:02PM  FDA approves revised prescribing information for use of Genzyme's Thyrogen at theflyonthewall.com
02:00PM  U.S. Prescribing Information for Thyrogen Revised to Include Use of Wider Range of Radioiodine in Patients Business Wire
10:30AM  Stocks: Insiders Buy at Regeneron, Valeant, and MDC Partners at Minyanville
09:13AM  Todays Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam at Motley Fool
25-Mar-14 07:27PM  Sanofi's Getting Back in the Game Gurufocus
02:30PM  From Plant to Prescription: 5 Ways Marijuana Made It to the Market Wall St. Cheat Sheet
24-Mar-14 06:32PM  Will This Stock Rule the Next Generation of Cholesterol Medicine? at Motley Fool
02:02PM  Endocyte Surges on Vynfinit News Zacks
01:04PM  Europe shares close lower as China, Crimea concerns remain at CNBC
12:30PM  Europe shares close lower as China, Crimea concerns remain at CNBC
11:43AM  Novo Nordisk Upgraded to 'Buy' at Fox Business
11:06AM  Europe shares extend losses on China, Crimea concerns at CNBC
10:42AM  Europe shares extend losses on China, Crimea concerns at CNBC
09:08AM  European markets retreat on China, Crimea concerns at CNBC
06:26AM  From Plant to Prescription: 5 Ways Marijuana Made It to the Market at Wall St. Cheat Sheet
05:50AM  European markets lower, China data weighs at CNBC
23-Mar-14 06:26PM  From Plant to Prescription: 5 Ways Marijuana Made It to the Market at Wall St. Cheat Sheet
01:32PM  Why Sony's PlayStation 4 Might Remain Scarce at Motley Fool
21-Mar-14 10:49AM  Storm The Castle Stock Of The Day: Sanofi (SNY) at TheStreet
08:06AM  Genzymes Lemtrada approved in Brazil for MS treatment at theflyonthewall.com
08:00AM  Transformational Late Stage Drugs Delivered Through Deal-Making at Forbes
08:00AM  Genzymes Lemtrada Approved in Brazil for Treatment of Multiple Sclerosis Business Wire
20-Mar-14 01:05PM  Rare LDL Cholesterol Disease Sufferers May Soon Have a New Drug at Motley Fool
09:31AM  Can Regeneron Keep Churning Out Blockbusters? at Motley Fool
19-Mar-14 12:01PM  Better Buy: Sirius XM vs. Sanofi at Motley Fool
18-Mar-14 08:30PM  Why Early Xbox One Sales Numbers Are Meaningless at Motley Fool
03:15PM  Shire Recalls Gaucher Drug Vpriv Zacks
09:00AM  Multiple Sclerosis Association of America's Nationwide Search Uncovers Inspiring Stories of People Living with MS Who Swim for Better Health PR Newswire
17-Mar-14 02:32PM  Will Pfizer Inc's Vaccine Strategy Pay Off? at Motley Fool
11:36AM  Amgen's PCSK9 Scores Against Genetic High Cholesterol at Investor's Business Daily
10:33AM  Stocks: Three Insiders Sell at FireEye; Regeneron Sees a Purchase at Minyanville
09:31AM  FDA Concerns Are the Least of These Drugs' Worries at Motley Fool
16-Mar-14 07:31PM  Up 755% Over the Past 3 Years, Can This Biotech Be Stopped? at Motley Fool
07:16PM  These International Dividend Stocks Offer Diversification and Income at Motley Fool
06:01PM  This Oral MS Drug Is Off to a Quick Start at Motley Fool
02:05PM  5 Big Pharma Stocks With the Strongest Ties to Emerging Markets at Motley Fool
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company's products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerMar 28Buy306.73306,94594,149,58320,018,090Mar 31 06:22 PM
Sanofi10% OwnerMar 27Buy311.01306,94595,463,96319,711,145Mar 31 06:21 PM
Sanofi10% OwnerMar 24Buy307.91306,94594,511,73418,790,310Mar 25 06:11 PM
Sanofi10% OwnerMar 21Buy321.22305,11598,008,22218,483,365Mar 25 06:10 PM
Sanofi10% OwnerMar 20Buy328.4157,95719,033,51118,178,250Mar 21 06:21 PM
Sanofi10% OwnerMar 19Buy327.899,7463,195,65118,120,293Mar 21 06:21 PM
Sanofi10% OwnerMar 17Buy328.5560,12819,755,23418,110,547Mar 18 06:58 PM
Sanofi10% OwnerMar 14Buy328.3655,58318,251,21518,050,419Mar 18 06:58 PM
Sanofi10% OwnerMar 12Buy334.69220,99573,964,41217,994,836Mar 14 05:11 PM
Sanofi10% OwnerMar 11Buy332.26180,71060,043,33617,773,841Mar 12 05:36 PM
Sanofi10% OwnerMar 10Buy328.73199,82265,687,43517,593,131Mar 12 05:36 PM
Sanofi10% OwnerMar 07Buy332.51241,81880,405,73317,393,309Mar 10 09:52 PM
Sanofi10% OwnerMar 07Buy316.2069,87322,093,65517,151,491Mar 10 09:51 PM
Sanofi10% OwnerMar 06Buy339.6080,40427,305,54617,081,618Mar 10 09:51 PM
Sanofi10% OwnerMar 03Buy338.12251,59485,070,11817,001,214Mar 05 08:36 PM
Sanofi10% OwnerFeb 07Buy287.3421,9866,317,45516,749,620Feb 10 06:46 PM
Sanofi10% OwnerFeb 06Buy286.70146,52542,008,39016,727,634Feb 10 06:46 PM
Sanofi10% OwnerFeb 05Buy282.00206,97858,367,10716,581,109Feb 06 07:30 PM
Sanofi10% OwnerFeb 04Buy286.44190,28654,504,78916,374,131Feb 06 07:30 PM
Sanofi10% OwnerFeb 03Buy283.46198,05856,141,71916,183,845Feb 04 07:11 PM
Sanofi10% OwnerJan 31Buy289.6610,9143,161,38315,985,787Feb 04 07:11 PM
Sanofi10% OwnerJan 28Buy278.5483,23523,184,32115,974,873Jan 29 08:20 AM
Sanofi10% OwnerJan 27Buy272.9674,68520,386,04415,891,638Jan 29 08:20 AM